Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31-April 1, 2016, Tours, France

Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence MAbImprove, the GDR 3260 Antibodies and therapeutic targeting, and the Grant Research program ARD2020 Biotherapeutics invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 - April 1, 2016 in Tours, France.